Jonathan W Riess

Sloan-Kettering Inst Can Research

$1,592,511

Attributed

$2,493,294

Total exposure

Grants

Lead (contact PI)

Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.

Funding over time

peak $1.9M · FY2021–25

$2M$1.5M$1M$500K$0

'21

'22

'23

'24

'25

Funding mix

By agency

NIH$6,025,723 · 3

By mechanism

U54$4,224,157 · 2

R01$1,801,566 · 1

Top collaborators

Luis Guillermo Carvajal Carmona7 shared
Paul K Paik3 shared

Most similar at Sloan-Kettering Inst Can Research

Same institution · by research overlap

Robert Andrew Cramer$16,202,316
Paul K Paik$900,783
Colin B Begg$14,027,064
Ronglai Shen$3,190,387
Jan-Philip Meyer$67,966

Others in their field

Other Emerging Leaders on “Signal Transduction”

Yunda Huang · Fred Hutchinson Cancer Center$53,064,276
Susan Abushakra · Alzheon, Inc.$47,265,244
Mathangi Thiagarajan · Leidos Biomedical Research, Inc.$37,695,154
Leonard Freedman · Leidos Biomedical Research, Inc.$32,575,497
Bala Raja · Luminostics, Inc.$28,624,460
Suzanne L Baker · University Of Pittsburgh At Pittsburgh$20,465,582

Research focus

Signal TransductionMalignant Neoplasm Of LungTargeted TreatmentCellsPharmaceutical PreparationsMutantMutationResistance MechanismTumorResistanceResponseTreatment ResponseCancer ModelOncogenesClinical TrialsFrequenciesFda ApprovedCaliforniaFrap1 GeneGeneticCancer SubtypesCancer Therapy Evaluation ProgramAffectEpidermal Growth Factor Receptor Tyrosine Kinase Inhibitor